Atzerrian jaten, zeliakia edo elikagai alergia dutenentzat

EBko arauek zer ematen dizuten

Hamabi alergeno nagusi — glutenarekin dituzten zerealak barne — EBn deklaratu behar dira, paketatutako elikagaietan eta elikagai zerbitzuan. Arauek nahikoa uniformea dira, zeliakia duen bidaiari batek estatu kideen artean mugitzean etiketa marko bera aurreikusten du, abantaila handia eta gutxietsi egiten dena.

Aldatzen dena betearazpena da, nola elikagai zerbitzuak agertzen duen (ahoz, menu batean, karpeta batean), eta egoerarekin kultura ezagutza. Herrialde batzuetan zeliakia gaixotasunaren inguruko kontzientzia publikoa handia da; beste batzuek lehentasun gisa tratatzen dute.

Sistema praktikoa

Lokaleko hizkuntzan itzulpen txartel bat lortu, egoera medikoki adieraziz, saihestu beharrekoak izendatuz, eta frijitzeko eta gainazal partekatuen aipamenarekin. Txartela sukaldera doa; ahozko esaldi bat ez.
Ikasi osagaien zerrenda irakurtzen, hizkuntza ez. Alergenoak tipografikoki azpimarratuta daude EBn, beraz, gainerakoak irakurri gabe aurki ditzakezu.
Gela bat hozkailu eta irabiagailu batekin erreserbatu. Bidaia zaila bat ohiko bihurtzen du.
Bidaia egunetarako elikagai segurua eraman. Aireportuak, geltokiak eta bidaia luzeak dira jendea harrapatzen den lekuak.
Lokaleko zeliakia edo alergia elkartea aurkitu. Europako herrialde gehienek bat dute, batzuk lekuen zerrendak argitaratzen dituzte.
Nahikoa medikamentua hartu — adrenalinako auto-injektoreak beharrezkoak direnean — eta errezeta gutuna eraman.

Segurua eta dokumentazioa

Egiaztatu bidaia asegurua zure egoera estaltzen duela, eta eraman medikamentuen dokumentazioa jatorrizko ontzian errezeta gutunarekin. EBen, Europako Osasun Aseguru Txartelak beharrezko estatuko tratamendua estaltzen du, bidaia asegurua ez dena eta ez du ordezkatzen.

Galdera ohikoak

Itzulpen txartelak benetan erabilgarriak al dira?

Bai, hitz egitea baino gehiago. Txartela sukaldera eman daiteke, erabakiak hartzen diren lekura.

Zeliakia duten Europako herrialdeak zeintzuk dira errazagoak?

Kontzientzia araudietatik gehiago aldatzen da. Zeliakia nazionaleko elkarteak iturri onenak dira orain arteko orokortze bat baino.

Nire medikamentuak muga gainditu ditzaket?

Orokorrean bai, jatorrizko ontzian errezeta gutunarekin. Egiaztatu substantzia kontrolatuak zehazki.

Zer gertatzen da atzerrian glutenarekin kutsatzen banaiz?

Sintomak eta hidratazioa kudeatu. Emaitza batzuen tratamendurik ez dago — ikusi gure zeliakiako gunea.

Erreferentziak

Hemen azpiko aipamen guztiak PubMed-en edo DOI bidezko jatorrizko peer-reviewed erregistroari lotzen diote. Hemen ez dago mediku aholkurik ordezkatzeko.

Selected laboratory-based biomarkers for assessing vitamin A deficiency in at-risk individuals Gannon BM, Huey SL, Mehta NH, et al. · The Cochrane database of systematic reviews · 2025 · Meta-analysis DOI PubMed 40433851 Full text
Towards shortening the duration of antibiotic therapy for Lyme borreliosis: a systematic review and meta-analysis Raffetin A, Henningsson AJ, Ornstein K, et al. · Infection · 2025 · Meta-analysis DOI PubMed 40246800
Non-pharmacological interventions designed to support carriers of multi-drug-resistant organisms (MDROs): a systematic literature review Gaube S, Pan M, Rath A, et al. · The Journal of hospital infection · 2025 · Systematic review DOI PubMed 40816599
Risk of anaphylaxis on commercial flights Turner PJ · Current opinion in allergy and clinical immunology · 2025 · Systematic review DOI PubMed 40643054 Full text
How Common Are Allergic Reactions During Commercial Flights? A Systematic Review and Meta-Analysis Turner PJ, Mamula J, Laktabi J, et al. · The journal of allergy and clinical immunology. In practice · 2023 · Meta-analysis DOI PubMed 37507067
Skin care interventions in infants for preventing eczema and food allergy Kelleher MM, Cro S, Cornelius V, et al. · The Cochrane database of systematic reviews · 2021 · Meta-analysis DOI PubMed 33545739 Full text
The effectiveness of anti-inflammatory and anti-seizure medication for individuals with single enhancing lesion neurocysticercosis: A meta-analysis and expert group-based consensus recommendations Abraham A, Bustos JA, Carabin H, et al. · PLoS neglected tropical diseases · 2021 · Meta-analysis DOI PubMed 33788843 Full text
Exit and Entry Screening Practices for Infectious Diseases among Travelers at Points of Entry: Looking for Evidence on Public Health Impact Mouchtouri VA, Christoforidou EP, An der Heiden M, et al. · International journal of environmental research and public health · 2019 · Systematic review DOI PubMed 31766548 Full text
Frequency, severity and causes of unexpected allergic reactions to food: a systematic literature review Versluis A, Knulst AC, Kruizinga AG, et al. · Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2015 · Systematic review DOI PubMed 24766413
EAACI food allergy and anaphylaxis guidelines: managing patients with food allergy in the community Muraro A, Agache I, Clark A, et al. · Allergy · 2014 · Clinical guideline DOI PubMed 24905609
Source attribution of human campylobacteriosis using a meta-analysis of case-control studies of sporadic infections Domingues AR, Pires SM, Halasa T, et al. · Epidemiology and infection · 2012 · Meta-analysis DOI PubMed 22214729
Effects of pregnancy and lactation prebiotics supplementation on infant allergic disease: A randomized controlled trial Palmer DJ, Cuthbert AR, Sullivan TR, et al. · The Journal of allergy and clinical immunology · 2025 · Randomised controlled trial DOI PubMed 39173718
One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial Kliewer KL, Gonsalves N, Dellon ES, et al. · The lancet. Gastroenterology & hepatology · 2023 · Randomised controlled trial DOI PubMed 36863390 Full text
Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial Jackson DJ, Bacharier LB, Gergen PJ, et al. · Lancet (London, England) · 2022 · Randomised controlled trial DOI PubMed 35964610 Full text
Basophil Activation Test: Bridging Allergy and Oncology for Diagnostic, Therapeutic and Prognostic Applications in AllergoOncology: An EAACI Position Paper Pascal M, Chauhan J, Knol E, et al. · Allergy · 2025 · Review DOI PubMed 40503572 Full text
The epithelial barrier theory and its associated diseases Sun N, Ogulur I, Mitamura Y, et al. · Allergy · 2024 · Review DOI PubMed 39370939 Full text
Travel Medicine Leung DT, LaRocque RC, Ryan ET · Annals of internal medicine · 2018 · Review DOI PubMed 29297035
The restaurant syndromes Settipane GA · New England and regional allergy proceedings · 1987 · Review DOI PubMed 3302666
Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023 Lancet (London, England) · 2025 · Journal article DOI PubMed 41092927 Full text
Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023 Lancet (London, England) · 2025 · Journal article DOI PubMed 41092926 Full text
Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 The Lancet. Neurology · 2024 · Journal article DOI PubMed 39304265 Full text
Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019 Shin YH, Hwang J, Kwon R, et al. · Allergy · 2023 · Journal article DOI PubMed 37431853 Full text